Zolgensma is used to help treat spinal muscular atrophy (SMA) in children younger than 2 years old. The recommended dosage for children is 1.1 x 10 14 vg per kilogram (kg)* of body weight.

Zolgensma is a prescription drug that’s used to treat spinal muscular atrophy (SMA) in young children. Zolgensma’s cost may depend on factors such as your child’s treatment plan and whether ...

Zolgensma is a one-time treatment, produced by Novartis, that can cure spinal muscular atrophy (SMA) in young children. SMA is a debilitating disorder that affects 1 in 10,000 births.

Zolgensma: A Remarkable New Treatment, An ICER Analysis, And A Poorly Justified Price Peter B. Bach June 18, 2019 10.1377/forefront.20190617.50453 Sections ...

And, a value-based price for Zolgensma was estimated at between $1.2 million to $2.1 million, given an alternative threshold of $100,000 to $150,000 per life year gained.

Zolgensma, Novartis' gene therapy treatment that was approved in May, costs $2.1 million and has often been referred to as the world's most expensive drug. David Lennon, president of AveXis, the ...

Novartis has argued that its therapy, approved last month as Zolgensma, is cost-effective even at $2.1 million. SMA is a progressive disease that gradually erodes muscular function. Patients often ...

Zolgensma may cause elevated enzymes, which can lead to serious liver damage. If your child has a history of liver problems, they may be at a higher risk of developing this side effect.

Ongoing follow-up in the START phase 1 study supported “the long-term favorable safety profile” of Zolgensma in children aged up to 6 years with spinal muscular atrophy type 1, according to ...

Zolgensma generated $634 million during the first half of the year, a 69% increase compared with 2020. The medicine is approved in more than 40 countries.

Another Zolgensma red flag, another delay in data reporting at Novartis' AveXis By Angus Liu Oct 31, 2019 11:42am Cell & Gene Therapy drug data drug safety gene therapy ...

Zolgensma is prescribed to treat SMA in certain children ages 2 years and younger. The dosage is based on the child’s body weight in kilograms (kg). For reference, 1 kg equals about 2.2 pounds (lb).